-
Product Insights
Dyslipidemia Disease - Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Dyslipidemia Global Clinical Trials Review, H1, 2019" provides an overview of Dyslipidemia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyslipidemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Type 1 Diabetes - Insulin Gene Therapy and Immuno-Modulators Dominate First-In-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration
Type 1 diabetes (T1D) is a chronic condition that occurs as a result of the autoimmune destruction of pancreatic beta (β) cells, which are responsible for producing insulin, a hormone needed for body cells to allow for the absorption of glucose in order to produce energy. Insulin is currently the mainstay treatment for T1D patients, and insulin therapy has significantly evolved over the last 90 years. Still, there is a pressing unmet need within T1D treatment landscape for more diverse,...
-
Sector Analysis
Obesity - Gut Hormone Receptors Retain Commercial Prominence
Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market’s clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely...
-
Sector Analysis
Type 1 Diabetes - Epidemiology Forecast to 2026
Type 1 diabetes, formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young adults before the age of 40 years. The condition, therefore, was also referred to as juvenile diabetes. Type 1 diabetes accounts for about 5–10% of all diabetes cases and occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin, a hormone that regulates blood sugar. If the condition is left untreated,...
-
Product Insights
Heterozygous Familial Hypercholesterolemia (heFH) - Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Heterozygous familial hypercholesterolemia (heFH) - Global Clinical Trials Review, H2, 2021" provides an overview of Heterozygous familial hypercholesterolemia (heFH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Heterozygous familial hypercholesterolemia (heFH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status...
-
Product Insights
Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Homozygous Familial Hypercholesterolemia (HoFH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Homozygous Familial Hypercholesterolemia (HoFH) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (HoFH), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
-
Product Insights
Familial Amyloid Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Familial Amyloid Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Familial Amyloid Cardiomyopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Familial Amyloid Cardiomyopathy, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news...
-
Product Insights
Methylmalonic Acidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Methylmalonic Acidemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Methylmalonic Acidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methylmalonic Acidemia, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
-
Product Insights
Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Cardiometabolic Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Cardiometabolic Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cardiometabolic Disease, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases....
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players
Non-Proliferative Diabetic Retinopathy (NPDR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.